SpeakerPARITY 2027
Tom Newcomer
Senior Vice President · Head of US Commercial
Samsung Bioepis
Experience over promotion
Voices shaping what comes next.
PARITY speakers bring practical evidence, hard-earned lessons, and a willingness to test ideas across functions.
Speaker program
Confirmed speakers for PARITY 2027.
PARITY 2027 brings senior operators and decision-makers into the conversation around biosimilar commercialization, market access, regulatory strategy, and adoption.
Additional speakers will be announced as participation is finalized. Proposals remain open for case-study-led sessions and practical operating perspectives.
SpeakerPARITY 2027
Piyush Modi
Director, Regulatory Affairs
Amneal Pharmaceuticals
SpeakerPARITY 2027
Elena Guillén
MD, PhD · Clinical Pharmacologist
Senior Researcher
Leiden University Medical Center
Open program tracks
Where your experience can contribute.
Track 01
Science, regulatory & clinical
Analytical similarity, totality of evidence, interchangeability, clinical design, and global pathway convergence.
Track 02
Manufacturing & commercial strategy
CDMO selection, scale-up, supply resilience, market access, pricing, uptake, and patent strategy.
Track 03
Partnering & investment
Licensing structures, transaction case studies, capital flows, portfolio strategy, and emerging classes.
Call for speakers
Bring the case study, not the sales deck.
Priority is given to proposals with a specific data point, operating lesson, or decision framework that peers can apply. The submission deadline is March 2027.
Start a submission
The formal submission portal will open in January 2027.
What we look for
A useful PARITY session is specific.
- 01A real program, transaction, policy change, or implementation challenge.
- 02A clear decision, result, or lesson that changed the approach.
- 03Evidence or experience that adds to the conversation instead of promoting a service.
- 04A willingness to engage with adjacent functions and answer direct questions.